Sue MacLeman Announced As CEO For MTPConnect

MTPConnect is pleased to announce that it has appointed Ms Sue MacLeman as Chief Executive Officer. Ms MacLeman will commence in her role April 2016 and will bring energy, expertise and insight to the role.

The industry-led Medical Technologies and Pharmaceuticals Industry Innovation Growth Centre (MTPConnect) has been established under the Australian Government's Industry Growth Centres Initiative. The release of the National Innovation and Science Agenda (NISA) in December 2015 made it clear that the opportunities for Australia have never been greater. MTPConnect will work to promote and accelerate innovation and entrepreneurship, to identify and remove barriers to success and to deliver sectoral competitiveness, collaboration and productivity.

Ms MacLeman has more than 25 years' experience as a pharmaceutical, biotechnology and medical technology executive with roles in corporate, medical, commercial and business development at Schering-Plough Corporation (now Merck), Amgen and Bristol-Myers Squibb. Ms MacLeman has also served as CEO and Board member of several ASX and NASDAQ listed companies in the sector and is currently a non-executive director at Reproductive Health Sciences Ltd. and Oventus Medical Ltd. Ms MacLeman moves to MTPConnect from her current role as Global Head Commercial at Mesoblast Ltd.

Dr Bronwyn Evans, the chair of MTPConnect commented:

'It is fantastic to have Sue MacLeman as our CEO. Sue will bring her vast experience and leadership to the role and will work closely with our MedTech and Pharma industries, researchers, agencies and associations. The Growth Centre aims to enhance Australia's successes in commercialising research, streamlining the regulatory system, increasing our sector skills and capability, and accessing the global value chain.'
 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.